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http://www.biomedcentral.com/1471-2261/13/35RESEARCH ARTICLE Open AccessTobacco smoking predicts depression and poorer
quality of life in heart disease
Lesley Stafford1,2,6*, Michael Berk3,4,5,6 and Henry J Jackson2Abstract
Background: We report on the prospective association between smoking and depression and health-related
quality of life (HRQOL) in patients with coronary artery disease (CAD).
Methods: Prospective study of 193 patients with assessment of depression occurring 3-, 6- and 9- months (T1, 2, and 3,
respectively) following discharge from hospital for a cardiac event. HRQOL was assessed at T3. T1 depression was
assessed by clinical interview; T2 and T3 depression was assessed by self-report. Smoking at time of cardiac event was
assessed by self-report. Multivariate analyses controlled for known demographic, psychosocial and clinical correlates of
depression.
Results: Smoking at the time of index cardiac event increased the likelihood of being diagnosed with Major Depressive
Disorder (MDD) at T1 by 4.30 [95% CI, 1.12-16.46; p < .05]. The likelihood of receiving a diagnosis of minor depression,
dysthymia or MDD as a combined group was increased by 8.03 [95% CI, 2.35-27.46; p < .01]. Smoking did not reliably
predict depression at T2 or T3 and did not reliably predict persistent depression. Smoking increased the likelihood of
being classified as depressed according to study criteria at least once during the study period by 5.19 [95% CI, 1.51-17.82;
p < .01]. Smoking independently predicted worse mental HRQOL.
Conclusions: The findings support a role for smoking as an independent predictor of depression in CAD patients,
particularly in the first 3 months post-cardiac event. The well-established imperative to encourage smoking cessation in
these patients is augmented and the findings may add to the evidence for smoking cessation campaigns in the primary
prevention of depression.
Keywords: Coronary artery disease, Depression, Smoking, Quality of lifeBackground
Tobacco smoking is a leading global cause of preventable
morbidity and mortality [1]. Despite a steady recent de-
crease in smoking prevalence in the general population,
smoking remains responsible for approximately 8% of the
overall burden of disease and injury [2]. Although there is
substantial recognition of the effect of smoking on phys-
ical morbidity, there is lesser appreciation of its connec-
tion to psychological morbidity, including depression.
Smoking is disproportionately common among individuals
with psychiatric disorders [3-6] and there is evidence that
it is noxious to mental health [7-9]. Smoking also appears* Correspondence: lesley.stafford@thewomens.org.au
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reproduction in any medium, provided the orto influence some of the pathophysiological pathways that
are germane to depression [10].
A reciprocal relationship exists between depression and
smoking such that depression is more common in
smokers than non-smokers, and smoking is more com-
mon in depressed versus non-depressed individuals. Stud-
ies in the general population have found that tobacco
smoking is a risk factor for depression [11,12]. A recent
study showed that the presence of smoking doubled the
risk of development of a de-novo episode of major depres-
sion in women followed up for 10 years [13].
Both depression [14-16] and smoking [17,18] are risk
factors for cardiac morbidity and mortality in patients
with CAD; however, previous data on the association be-
tween tobacco smoking and depression in CAD patients
are inconsistent. Some studies report no association
[19-21] and others report that smoking is a risk factorl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lysis of data from a longitudinal study of depression in
CAD to investigate the prospective association between
smoking and depression. Based on the weight of evi-
dence, we hypothesized that smoking would be associ-
ated with increased risk for the subsequent onset of
depression among recently hospitalized CAD patients
when known correlates of depression were controlled a
priori. These correlates include clinical variables such as
disease severity, body mass index (BMI), having under-
gone coronary artery bypass graft (CABG) surgery, dia-
betes, alcohol intake, functional disability, prior history
of depression, Generalized Anxiety Disorder (GAD),
neuroticism, and known socio-demographic factors such
as gender, income, marital status and social support,). As
a secondary outcome, we investigated the association
between smoking and health-related quality of life
(HRQOL). A deleterious impact of smoking on HRQOL
has been reported in cross-sectional samples of the gen-
eral population [24-26]. Only one prior longitudinal
study has explicitly examined this association in CAD
patients and showed that continued smoking after per-
cutaneous transluminal coronary angioplasty (PTCA)
significantly diminished the HRQOL benefits of this pro-
cedure [27]. We further hypothesized that smoking
would be associated with worse HRQOL. The aims of
the study were therefore to investigate the prospective
association between smoking and depression and smok-
ing and HRQOL in a cohort with cardiovascular disease.
Methods
Sample
Participants were recruited between May 2005 and March
2006 from a tertiary hospital in regional Australia that
serves a catchment area shown to be representative of the
broader Australian community [28]. All English-speaking,
consenting patients who were hospitalized for PTCA, myo-
cardial infarction (MI) or CABG during this time were eli-
gible for participation. According to discharge diagnoses,
528 patients were treated for these presentations during
the study period. Patients with different CAD presentations
were regarded as a homogenous group based on evidence
that the association between depression and CAD is found
across all subgroups of CAD patients with similar prognos-
tic effects for cardiac [14,29] and HRQOL [30,31] out-
comes. Participants were recruited by postal invitation and
follow-up phone-call 6 weeks post-discharge. Reasons for
non-participation were death (n = 13), non-English speak-
ing (n = 16), unable to consent (n = 9), medically unwell
(n = 9), depression (n = 3) and no given reason (n = 249).
Agreement to participate was obtained from 229 patients.
The study received ethics approval from the Barwon
Health Human Research and Ethics Committee and all
participants gave written informed consent.Procedures
Data were collected at 3- (T1), 6- (T2) and 9 months (T3)
after hospital discharge. Baseline assessment was under-
taken 3 months post-discharge, rather than during admis-
sion, as well as to avoid potential confounding of the effects
of acute illness and stress associated with hospitalization
with the assessment of predictor variables and to minimize
the burden on participants. Other studies [22,23,32] have
highlighted difficulties in reliably identifying patients in
whom depression will emerge, persist or worsen only on
the basis of level of depressive symptomatology present
during hospitalization. Structured clinical interviews were
administered telephonically at T1. Telephonic administra-
tion of structured clinical interviews has been found to be
valid and reliable [33,34]. For analyses, participants were
assigned to a diagnostic group “major depressive disorder”
(MDD) or to a broader group “any depressive disorder”
(‘ADD’). The latter comprised, in addition to participants
with MDD, participants with minor depression and
dysthymia.
Participants were also mailed self-report questionnaires
at T1, T2 and T3. T1 questionnaires assessed neuroticism,
social support, and functional disability. The depression
self-report measure was administered at T2 and T3. The
structured clinical interview was used to establish a diagno-
sis while the self-report depression measure enabled track-
ing of depression change over time. HRQOL data were
collected at T3. Relevant clinical and socio-demographic
data were collected by self-report and from medical
records at T1.
Measures
Clinical data, including discharge diagnosis, antidepres-
sant therapy at discharge, disease severity and the pres-
ence of hypertension and diabetes, were obtained from
medical records. Disease severity was measured with left
ventricular ejection fraction (LVEF). BMI was computed
based on self-reported height and weight (kg/m2) at the
time of the index event. Data on commencement of anti-
depressant therapy after index event, attendance at car-
diac rehabilitation, marital status, annual household
income, prior history of depression, and tobacco use and
alcohol consumption at the index event were gathered
by self-report. Alcohol consumption was considered ex-
cessive if greater than the quantity recommended by the
National Heart Foundation of Australia (≤7 and 14
standard drinks per week for women and men, respect-
ively) [35]. Low household income was categorized as ≤
$20 000 (Australian).
Clinical depression and GAD were assessed using the
Mini International Neuropsychiatric Interview Version 5
(M.I.N.I.) [36,37], a diagnostic structured interview com-
patible with ICD-10 and DSM-IV criteria, and similar to
the Structured Clinical Interview for DSM-IV Disorders
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excellent psychometric properties and has been validated
against the SCID-Patient Version [39] and the Composite
International Diagnostic Interview (CIDI) [36,37,40,41]. M.
I.N.I modules for depression, GAD and dysthymia were ad-
ministered. Major depressive disorder (MDD) was diag-
nosed if participants fulfilled DSM-IV criteria of at least
one core criterion (depressed mood or anhedonia) and at
least four additional criteria within a 2-week duration.
With the use of the same module, minor depression was
diagnosed if participants fulfilled at least one core criterion
and one to three additional criteria within a 2-week period.
Depressive symptomatology was measured with the 7-
item depression subscale of the Hospital Anxiety and
Depression Scale (HADS) [42]. The HADS has well-
established psychometric properties [43,44] and is widely
used in studies with cardiac patients [45-47]. Possible
scores range from 0 to 21. Higher scores denote greater
depressive symptomatology. Cronbach’s alpha at T1, T2
and T3 were .81, .82, and .84, respectively. In accordance
with previous data [44,48-50], a score ≥ 8 was considered
to indicate depression.
Social support was assessed with the psychometrically-
robust [51-53] and widely-used [49,54-56] 12-item Multi-
dimensional Scale of Perceived Social Support (MSPSS)
[57]. This scale measures support from family, friends and
a significant other. The total score ranges from 7 to 84
with higher scores indicating higher levels of support.
Cronbach’s alpha was .93.
Neuroticism was measured with a 10-item scale from the
self-report version of the NEO PI-R [58], the IPIP-NEO
[59]. Scores range from 10 to 50 with higher scores indicat-
ing greater neuroticism. The IPIP-NEO has been shown to
be reliable [60] and valid [58,61] and its factor structure has
been confirmed [62,63]. Cronbach’s alpha was .88.
HRQOL was measured with the Short Form-36 (SF-36)
[64], an inventory that assesses eight domains of HRQOL:
physical functioning, bodily pain, fatigue, role limitations
due to physical health problems, emotional functioning,
role limitations due to emotional problems, social func-
tioning and general health perception. Aggregate summary
scores for physical functioning (PCS) and mental function-
ing (MCS) were calculated according to the standard algo-
rithm [64]. Higher scores denote better functioning.
Psychometric evidence suggests that the SF-36 is the most
reliable, valid, and sensitive generic measure of HRQOL
for use in CAD patients [65]. Cronbach’s alpha values for
the eight subscales at T1 and T3 ranged from .80 to .92,
and .81 to .93, respectively.
Functional disability was measured using the 10 items
from the SF-36 that assess physical functioning. Items
include activities such as walking one block and
climbing a flight of stairs. In the original context these
items assess limitations on physical activities. Here, theresponse format was altered to assess the severity of
symptoms experienced when performing these physical
tasks. The items are similar to measures like the
Canadian Cardiovascular Society for angina severity [66]
and the New York Heart Association classification cri-
teria for the prescription of physical activity for cardiac
patients [67]. Responses include I do not experience
symptoms, I experience mild symptoms, I experience se-
vere symptoms, and I am not able to perform this activ-
ity. Scores range from 0 to 30 with lower scores
indicating greater functional disability.
Analysis
Data were analysed using SPSS. All tests were two-tailed
and α was .05. Univariate analyses comprised Chi-square
and independent sample t-tests, as appropriate. Multivari-
ate analyses to predict the association between smoking
and depression used direct logistic regression. All pre-
dictor variables were entered in one block. Regression co-
efficients, Wald statistics, odds ratios (ORs) and 95%
confidence intervals were calculated. Regression analyses
for T1 comprised predicting MDD and ‘ADD’, as defined
above. At T2 and T3, depression was defined by a HADS
score ≥8. Two additional independent variables were cre-
ated. Participants were assigned a priori to a ‘persistently
depressed’ group if they were classified as depressed at T1,
T2 and T3. Participants were assigned to an ‘ever de-
pressed’ group if they were classified as depressed at T1,
T2 or T3. For these two variables, membership of the
‘ADD’ group constituted T1 depression. Multivariate ana-
lyses to predict physical and mental HRQOL at T3 were
performed using standard regression.
Results
Characteristics of the sample
T1 questionnaires were completed by 193 of the 229
recruited patients (84%; or 37% of all patients treated
during the study period included those deceased and in-
eligible). According to discharge diagnoses, these 193
participants were treated for MI (n = 13, 7%), CABG
(n = 91, 47%), PTCA (n = 35, 18%), MI and CABG
(n = 21, 11%), and MI and PTCA (n = 35, 18%). [To fa-
cilitate analysis, this variable was categorized into
CABG vs MI/PTCA]. Compared to non-participants,
participants were significantly more likely to be male [χ2
(1, N = 528) = 5.93, P = .02] and were, on average, youn-
ger [t(526) = 3.12, P < .01]. The mean (SD) age for par-
ticipants versus non-participants was 64.14 (10.37)
versus 67.31 (11.70), respectively. Twenty-eight partici-
pants did not return their questionnaires for an un-
specified reason, 3 withdrew due to physical illness and
4 withdrew due to depression. There were no significant
gender differences between those who completed T1
questionnaires and those who did not [χ2(1, N = 229) = .64,
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cantly younger than respondents [t(227) = −2.13, P < .03].
The mean (SD) age for non-responders was 59.94 (13.22).
At T2, 189 of the 193 T1 participants remained. By T3,
184 of the 193 T1 participants remained (95%; or 35% of
the original patient group (184 of 528)). One participant
had formally withdrawn due to depressive illness and 8
participants did not return their questionnaires for un-
specified reasons. There were no gender or age differences
between participants who completed T2 and T3 question-
naires and those who did not. Baseline clinical, socio-
demographic, and psychosocial data for the sample and
for non-smokers versus smokers are described in Table 1.
Association between smoking and depression
Twenty-seven participants (14%) were smokers at the time
of index event. At T1, 35 (18%) participants were diag-
nosed with MDD and 54 (28%) with ‘ADD’. Univariate
analyses (Table 1) showed that compared to non-smokers,
participants who were smokers at the time of the index
cardiac event were significantly younger [t(191) = 3.73,
P < .001]; less likely to have undergone CABG [χ2(1, N =
193) = 10.4, P = .001], less likely to attend cardiac rehabili-
tation [χ2(1, N = 187) = 6.98, P = .02], perceived less socialTable 1 Characteristics of sample at T1
Non-smoker (n =
Male, n (%) 137 (83)
Age (years), M±SD (range)*** 65.23±9.81
Income < AU$20 000, n (%) 54 (33)
Married, n (%) 131 (79)
Hypertension, n (%) 127 (77)
Diabetes, n (%) 40 (24)
CABG, n (%)** 104 (63)
BMI (kg/m2), M±SD (range) 28.07±4.28
LVEF < 30% n (%) 11 (7)
Alcohol - Excessive 34 (12)
Functional status, M±SD (range) 24.81±4.57
MDD*** 23 (14)
ADD*** 36 (33)
GAD* 27 (16)
History of depression 57 (34)
Antidpressants at T1, n (%) 17 (10)
Antidepressants T1-T3, n (%) 13 (8)
Neuroticism, M±SD (range)** 26.48±8.50
Social support, M±SD (range)** 70.25±11.19
Attended cardiac rehabilitation†, n (%)* 121 (76)
ADD Any depressive disorder, BMI body mass index, CABG coronary artery bypass g
fraction, MDD Major Depressive Disorder.
† Known for n = 187.
*P < .05 **P < .01 *** P < .001.support [t(191) = 2.70, P < .01], reported higher levels of
neuroticism [t(31.72) = −2.79, P < .01] and were more
likely to receive a diagnosis of GAD [χ2(1, N = 193) = 6.47,
P = .01], ‘ADD’ [χ2(1, N = 193) = 23.32, P < .001] or MDD
[χ2(1, N = 193) = 14.64, P < .001] at T1 (i.e., 3 months
later).
Logistic regression analyses to predict depression are
shown in Table 2 (MDD, ‘ADD’, and T2 Depression) and
Table 3 (T3 Depression, ‘Persistently depressed’, and ‘Ever
depressed’). Inspection of the ORs showed that smoking
at the time of index cardiac event increased the likeli-
hood of being diagnosed with MDD at T1 by 4.30 [95%
CI, 1.12-16.46; P < .05], an OR second only to that asso-
ciated with a diagnosis of GAD. In the analysis to predict
‘ADD’ at T1, smoking had an OR of 8.03 [95% CI, 2.35-
27.46; P < .01] and was the strongest independent pre-
dictor of outcome of all the available variables. At T2
and T3, 24 (13%) and 29 (16%) participants, respectively,
reported a HADS score ≥ 8. Smoking did not reliably
predict a depression at T2 and T3. Fourteen participants
(8%) were assigned to the ‘persistently depressed’ group
and 60 (33%) were assigned to the ‘ever depressed’
group. Smoking was not reliably associated with classifi-
cation as ‘persistently depressed’. Smoking increased the166) Smoker (n = 27) Total (N = 193)
19 (70) 156 (81)
57.44±11.40 64.14±10.37 (38–91)
9 (33) 63 (33)
15 (56) 146 (76)
23 (85) 150 (78)
5 (19) 45 (23)
8 (30) 112 (58)
27.55±3.92 28.00±4.22 (20–40)
0 (0) 11 (8)
6 (22) 40 (21)
23.97±6.33 24.09±6.11 (0–30)
12 (44) 35 (18)
18 (67) 54 (28)
10 (37) 37 (19)
10 (37) 67 (35)
3 (11) 20 (11)
3 (11) 16 (8)
32.44±10.56 27.32±9.02 (10–50)
63.89±12.34 69.36±11.54 (21–84)
13 (50) 134 (72)
raft surgery, GAD Generalized Anxiety Disorder, LVEF left ventricular ejection
Table 2 Direct logistic regression analyses to predict the association between smoking and depression (MDD, ’ADD’
and T2 Depression)
T1 MDD (N = 193) T1 ‘ADD’ (N = 193) T2 Depression (N = 189)
B SE Wald OR 95% CI 95% CI 95% CI
Variable Lower Upper B SE Wald OR Lower Lower B SE Wald OR Lower Upper
Male -.24 .64 .14 .79 .23 2.77 .19 .59 .10 1.21 .38 3.83 .57 .70 .65 1.76 .44 6.97
Married .79 .74 1.15 2.21 .52 9.43 .48 .63 .596 1.62 .47 5.56 .67 .74 .81 1.96 .46 8.39
Income .57 .61 .86 1.76 .53 5.82 .12 .54 .05 1.12 .39 3.24 -.20 .65 .09 .82 .23 2.96
LVEF −18.86 1.10 .00 .00 .00 . -.42 1.22 .12 .65 .06 7.12 −18.51 1.13 .00 .00 .00 .
BMI -.04 .06 .41 .96 .85 1.09 .04 .05 .74 1.05 .95 1.15 -.02 .07 1.00 .98 .85 1.12
Diabetes -.35 .66 .29 .70 .19 2.54 -.51 .58 .80 .60 .19 1.85 -.65 .71 .84 .52 .13 2.09
Smoking 1.46 .69 4.52* 4.30 1.12 16.46 2.08 .63 11.05** 8.03 2.35 27.46 .16 .71 .05 1.17 .29 4.69
Alcohol -
excessive
-.70 .66 1.13 .50 .14 1.81 -.07 .55 .02 .93 .32 2.71 .05 .64 .01 1.05 .30 3.71
History of
depression
.94 .53 3.13 2.56 .90 7.23 .75 .46 2.65 2.12 .86 5.22 .68 .56 1.51 1.98 .67 5.88
GAD 1.87 .60 9.56** 6.50 1.98 21.09 1.81 .55 10.74** 6.09 2.07 17.93 .05 .69 .01 1.06 .27 4.11
Neuroticism .08 .04 4.37* 1.08 1.01 1.16 .09 .03 7.67** 1.09 1.03 1.16 .08 .04 4.32* 1.09 1.01 1.17
Social
support
.01 .03 .15 1.01 .96 1.06 .01 .02 .20 1.01 .97 1.05 -.06 .02 6.35* .94 .90 .99
Functional
status
-.07 .04 2.64 .93 .86 1.01 -.08 .04 5.15* .92 .86 .99 -.11 .05 5.76* .90 .82 .98
CABG .91 .53 2.94 2.49 .88 7.04 1.10 .45 6.07* 3.01 1.25 7.24 1.23 .57 4.64* 3.43 1.12 10.54
Constant −3.83 3.25 1.38 .02 −5.43 2.69 4.06 .00 .96 3.06 1.00 2.62
ADD Any depressive disorder, BMI body mass index, CABG Coronary artery bypass graft surgery, GAD Generalized Anxiety Disorder, Income Annual household
income ≤ AU$20 000 LVEF left ventricular ejection fraction <30%, MDD Major Depressive Disorder.
*P < .05 **P < .01 *** P < .001.
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of 5.19 [95% CI, 1.51-17.82; P < .01] and was again the
most important predictor of depression in this analysis.
Association between smoking and HRQOL
Correlations between T1 demographic, psychosocial and
clinical variables and T3 mental and physical HRQOL are
shown in Table 4. Multivariate analyses to investigate the
association between smoking and HRQOL at T3 are
shown in Table 5. The model to predict MCS explained
47% of the variance in outcome [F(14,184) = 10.85,
P < .001] and showed that smoking was significantly asso-
ciated with MCS (P < .001), explaining approximately 4.8%
of unique variance. Neuroticism was the most important
predictor and contributed approximately 6.7% of unique
variance. The model to predict PCS explained 46% of the
variance in outcome [F(14,184) = 10.24, P < .001]. Smoking
was not an independent predictor of PCS (P = .98).
Discussion
Our findings indicate that in the presence of well-known
confounders, exposure to smoking is independently as-
sociated with a 4.30- and a 8.03-fold increase in odds for
MDD and a diagnosis of minor depression, dysthymia or
MDD as a combined group (‘ADD’), respectively, 3months following cardiac hospitalization. Smoking in-
creased the likelihood of being classified as depressed
according to study criteria at least once during the 9
months of the study period by an OR of 5.19. Despite this
finding, there was no significant association between
smoking and depression at T2 or T3, and given that smok-
ing status and depression were measured simultaneously
at T1, an independent prospective association cannot be
clearly concluded from these data. This study provides evi-
dence consistent with the hypothesis that tobacco smok-
ing is an independent predictor of depression and adds to
the evidence that smoking is noxious to mental health
[68]. Consistent with prediction, smoking was associated
with worse mental HRQOL. There was, however, no asso-
ciation between smoking and physical HRQOL. These
findings are similar to Rumsfeld et al. (2003) [69] who
reported that tobacco smoking was independently predict-
ive of 6-month mental but not physical HRQOL in CAD
patients who underwent revascularization.
The mechanisms through which smoking is associated
with depression are likely to be complex, involving bio-
genetic, psychological and environmental factors. Indeed,
studies in depression have supported a tri-directional rela-
tionship driven by mutually reinforcing effects and shared
causal factors [70]. These factors include genetic and
Table 3 Direct logistic regression analyses to predict the association between smoking and depression (T3 Depression,
‘Persistently depressed’ and ‘Ever depressed’)
T3 Depression (N = 184) ‘Persistently depressed’ (N = 184) ‘Ever depressed’ (N = 184)
B SE Wald OR 95% CI 95% CI 95% CI
Variable Lower Upper B SE Wald OR Lower Lower B SE Wald OR Lower Upper
Male .31 .68 .21 1.37 .360 5.20 .04 .82 .00 1.04 .21 5.15 .82 .62 1.72 2.26 .67 7.66
Married 1.87 .93 4.11* 6.52 1.06 39.89 .60 1.10 .31 1.82 .235 14.63 .91 .68 1.79 2.48 .66 9.39
Income -.81 .73 1.23 .45 .11 1.86 .01 .81 .00 1.01 .21 4.94 .01 .55 .00 1.01 .35 2.96
LVEF −18.54 1.10 .00 .00 .00 . −17.66 1.13 .00 .00 .00 . −1.08 1.19 .84 .34 .03 3.45
BMI .10 .06 3.04 1.11 .99 1.25 -.05 .09 .33 .95 .80 1.13 .03 .05 .47 1.03 .94 1.14
Diabetes 1.11 .63 3.12 3.05 .88 10.51 .15 .84 .03 1.16 .23 5.99 -.78 .58 1.83 .46 .15 1.42
Smoking .43 .74 .34 1.54 .36 6.58 .06 .91 .01 1.07 .18 6.32 1.65 .63 6.84** 5.19 1.51 17.82
Alcohol -
excessive
.18 .72 .06 1.19 .29 4.91 -.61 .93 .43 .54 .09 3.35 .34 .56 .36 1.40 .47 4.23
History of
depression
.62 .55 1.27 1.86 .63 5.55 1.69 .77 4.87* 5.41 1.21 24.23 .15 .47 .10 1.16 .46 2.93
GAD 1.38 .65 4.53* 3.99 1.12 14.28 1.04 .876 1.45 2.83 .52 15.48 1.43 .56 6.45* 4.16 1.38 12.48
Neuroticism .06 .04 2.59 1.06 .99 1.14 .04 .05 .52 1.04 .94 1.14 .13 .03 14.41*** 1.14 1.06 1.21
Social
support
-.07 .03 5.91* .94 .89 .99 -.04 .03 1.77 .96 .91 1.02 -.02 .02 .62 .98 .94 1.03
Functional
status
-.13 .05 5.96* .88 .80 .98 -.06 .06 .95 .95 .84 1.058 -.18 .05 15.52*** .84 .77 .92
CABG .49 .56 .78 1.63 .55 4.84 1.13 .72 2.51 3.11 .76 12.653 .75 .44 2.88 2.11 .89 4.98
Constant −2.01 3.07 .43 .13 .04 .82 .00 1.04 .21 5.153 −2.15 2.56 .71 .12
ADD Any depressive disorder, BMI body mass index, CABG Coronary artery bypass graft surgery, GAD Generalized Anxiety Disorder, Income Annual household
income ≤ AU$20 000, LVEF left ventricular ejection fraction <30%, MDD Major Depressive Disorder.
*P < .05 **P < .01 *** P < .001.
Table 4 Correlations between T1 demographic, psychosocial and clinical variables and T3 mental and physical HRQOL
Variable 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1. Male 1
2. Married .28*** 1
3. Income -.14 -.27*** 1
4. LVEF .06 -.02 .07 1
5. BMI -.06 .09 -.01 -.05 1
6. Diabetes -.04 -.06 .17* .02 .10 1
7. Smoking -.11 -.19*** .01 -.10 -.04 -.05 1
8. Alcohol -excessive .18* .08 -.06 -.07 -.07 -.13 .02 1
9. History ofdepression -.06 -.09 .05 -.09 .09 -.04 .02 .00 1
10. GAD -.03 .00 .05 -.12 .04 -.08 .18* .01 .23*** 1
11. Neuroticism -.10 .03 .15* -.11 .04 .03 .23*** .00 .34*** .49** 1
12. Social support .06 .34*** -.10 .04 .00 .04 -.20*** .05 -.08 -.19** -.12 1
13. Functional status .20*** .19*** -.42*** -.07 -.07 -.20*** .02 .11 -.16* -.06 -.17* .11 1
14. CABG -.12 -.06 0.08 -.03 .00 -.10 .23** .06 -.03 .09 .13 .00 .01 1 -.15*
15. MCS .100 .02 -.06 .09 -.26*** -.08 -.36*** .07 -.32*** -.41*** -.54*** .22*** .21*** 1
16. PCS .16* .16* -.29*** -.01 -.07 -.23*** -.04 .06 -.28*** .00 -.21*** .06 .61*** .18*** 1
BMI body mass index, CABG Coronary artery bypass graft surgery, GAD Generalized Anxiety Disorder, Income Annual household income ≤ AU$20 000,
LVEF left ventricular ejection fraction <30%, MCS Mental Component Summary score of the SF-36, PCS Physical Component Summary score of the SF-36.
*P < .05 ** P < .01 *** P < .001.
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Table 5 Multiple regression analyses to predict the association between smoking and HRQOL at T3
Physical HRQOL at T3 (N = 184) Mental HRQOL at T3 (N = 184)
Variable 95% CI for β 95% CI for β
B SE β Lower Upper B SE β Lower Upper
Constant 2191.21 471.57 1260.29 3122.14 5094.85 530.41 4047.77 6141.92
Male −1.29 134.42 .00 −266.64 264.06 −78.07 151.19 -.03 −376.53 220.39
Married 82.47 135.80 .04 −185.61 350.56 −77.48 152.75 -.03 −379.01 224.06
Income −3.39 120.15 -.00 −240.57 233.80 151.72 135.14 .07 −115.06 418.50
LVEF 67.40 212.32 .02 −351.75 486.55 −47.46 238.81 -.01 −518.90 423.99
BMI 2.54 11.90 .01 −20.95 26.02 −50.37 13.38 -.22*** −76.78 −23.95
Diabetes −240.51 120.41 -.12* −478.22 −2.81 −148.65 135.44 -.07 −416.01 118.72
Smoking −3.08 154.25 -.00 −307.58 301.42 −687.49 173.49 -.24*** −1029.98 −345.01
Alcohol - excessive −15.11 127.08 -.01 −265.97 235.75 125.54 142.93 .05 −156.62 407.69
History of depression −325.52 114.85 -.18** −552.24 −98.79 −252.56 129.18 -.12 −507.57 2.45
GAD 249.36 146.24 .11 −39.33 538.04 −378.52 164.48 -.15* −703.22 −53.82
Neuroticism −10.02 6.79 -.10 −23.42 3.38 −35.86 7.64 -.33*** −50.93 −20.79
Social support -.02 .04 -.03 -.09 .054 .06 .04 .09 -.02 .15
Functional status .06 .01 .55*** .05 .074 .02 .01 .12 -.00 .03
CABG −248.66 104.18 -.14 −454.33 −43.00 −106.99 117.18 -.05 −338.31 124.33
BMI body mass index, CABG Coronary artery bypass graft surgery, GAD Generalized Anxiety Disorder, HRQOL Health related quality of life, Income Annual
household income ≤ AU$20 000, LVEF left ventricular ejection fraction <30%.
*P < .05 ** P < .01 *** P < .001.
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pression and smoking; smoking-induced neurobiological
changes that might predispose to depression; the transient
alleviation of depressive symptoms and psychotropic side
effects with smoking; and increased smoking as part of an
agitated mental state.
Homeostatic compensation ensures that over time and
with adaptation, agents that initially induce short-term al-
terations in mood later tend to produce contrary effects.
For example, the acute effects of alcohol (i.e., anxiolysis and
sleep induction) are characteristically the converse of the
withdrawal pattern (i.e., anxiety and insomnia). Cigarette
smoking can be conceptualised as a chronic dysphoric
withdrawal state punctuated by brief reinforcing intoxica-
tions. Smoking addiction, in common with other addic-
tions, is mediated via the dopaminergic reward pathway,
and dopamine has a key role in depression [71]. Smoking
dysregulates the striatal D2 receptor, which may play a
shared role in both its pathway to addiction and its effect
on mood [72].
The status of both tobacco smoking and depression as
risk factors for cardiac morbidity and mortality is sup-
ported by evidence of shared pathways. For instance,
cigarette smoke contains high amounts of oxidative free
radicals, including nitric oxide [73]. These free radicals
have a complex effect on the oxidative defence system,
inducing a direct oxidative attack and simultaneously
upregulating antioxidant defences [73]. Oxidative stress
is implicated in the pathophysiology of both depression[74] and cardiovascular disease [75]. Cigarette smoking
has also been associated with raised levels of C-reactive
protein [76], suggesting the stimulation of a chronic in-
flammatory state, which again, is described in both de-
pression and cardiovascular disorders [77,78].
Strengths of the study include its prospective design, the
low attrition rate and the inclusion of well-known con-
founders of depression such as history of depression, neur-
oticism, anxiety and functional status. We acknowledge
that the generalizability of our findings is limited by sam-
ple bias. Since respondents were more likely to be male
and were on average younger than non-respondents, these
findings should be cautiously applied to older, female
CAD patients. Indeed, there is evidence that women and
men with CAD have different medical, functional and psy-
chosocial profiles [80–82]. Also, taking into account all pa-
tients treated during the study period, regardless of
eligibility for the study, the compliance rate was low (193
of 528 = 37%). It is possible that patients with depression
were less likely to participate in the study potentially
resulting in an underestimation of the effect of smoking.
Duration and exposure of smoking prior to depression on-
set are unknown. Baseline measures were not conducted
prior to the cardiac interventions. Exact depression status
was not known at the time of index cardiac event for the
reasons explained earlier, but prior history of depression,
the most important risk factor for subsequent depression,
was included in all multivariate analyses. Still, it is plaus-
ible that depression led to tobacco use and that smokers
Stafford et al. BMC Cardiovascular Disorders 2013, 13:35 Page 8 of 10
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It is noted that LVEF can be an imprecise measure of dis-
ease severity but was the most consistently available meas-
ure in the medical records. We acknowledge that although
ORs were significant and notable, the confidence intervals
were wide. This has implications of imprecision in estimat-
ing the true effect size and may be addressed in future
studies with larger sample sizes.
Individuals often need risk to be personalized before a
health warning is internalized to the point that it precipi-
tates a decision to act. The message that smoking is an in-
dependent predictor of depression in someone who
experiences the distress of depression, may be a catalyst for
change. This information may work in parallel with the no-
tion that the diagnosis of a smoking-related physical illness
can precipitate motivation for smoking discontinuation.
The demonstration of the association between smoking
and mood and HRQOL augments the well-established
physical imperative to encourage smoking cessation in pa-
tients with CAD [79]. This message similarly needs to be
routinely communicated to depressed individuals.
Conclusions
Adjusted for well-known confounders of depression,
smoking was independently associated with depression
in patients with heart disease. Smoking was an independ-
ently associated with poor mental HRQOL. These data
reinforce the imperative to encourage smoking cessation
in patients with heart disease, and add to the evidence for
smoking cessation campaigns in the primary prevention of
depression [8].
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